Although several murine mAbs that have been humanized became useful therapeutic agents against a few malignancies, therapeutic Abs are not yet available for the majority of the human cancers because of our lack of knowledge of which antigens (Ags) can become useful targets. In the present study we established a procedure for comprehensive identification of such Ags through the extensive isolation of human mAbs that may become therapeutic. Using the phage-display Ab library we isolated a large number of human mAbs that bind to the surface of tumor cells. They were individually screened by immunostaining, and clones that preferentially and strongly stained the malignant cells were chosen. The Ags recognized by those clones were isolated by immunoprecipitation and identified by MS. We isolated 2,114 mAbs with unique sequences and identified 21 distinct Ags highly expressed on several carcinomas. Of those 2,114 mAbs 356 bound specifically to one of the 21 Ags. After preparing complete IgG1 Abs the in vitro assay for Ab-dependent cell-mediated cytotoxicity (ADCC) and the in vivo assay in cancer-bearing athymic mice were performed to examine antitumor activity. The mAbs converted to IgG1 revealed effective ADCC as well as antitumor activity in vivo. Because half of the 21 Ags showed distinct tumor-specific expression pattern and the mAbs isolated showed various characteristics with strong affinity to the Ag, it is likely that some of the Ags detected will become useful targets for the corresponding carcinoma therapy and that several mAbs will become therapeutic agents.phage Ab library ͉ therapeutic Ab ͉ tumor-associated antigen S ince the discovery of a method to produce mAbs numerous scientists have been trying to identify and produce mAbs that could be used for immunotherapy against various malignancies. The success for example of alemtuzumab against CD52, trastuzumab against HER2, and rituximab against CD20 for treatment of chronic lymphocytic leukemia, breast cancer, and nonHodgkins lymphoma, respectively (1-3), suggests that mAbs are likely to become very important therapeutic agents also against a wider range of cancers. However, for the majority of the human cancers useful therapeutic Abs are not yet available because of our lack of knowledge of which antigens (Ags) are likely to become useful targets (4). Therefore, several groups of investigators have been trying to identify other potential Ags as targets for immunotherapy using microarray technology (5, 6). Although many differences in transcripts have been revealed between malignant cells and the normal counterpart cells, it will take more time and laborious work to examine which Ags could be targets and to prepare therapeutic Abs against them. Furthermore, the presence of a large amount of transcripts does not always indicate expression of a large amount of the proteins.Our experimental approach was designed in the opposite way to the strategy with the microarray technology mentioned above and was based on the phage-display technology (7). First we isolate...
A 64-year-old woman presented with exertional dyspnea. The case was diagnosed as mixed connective tissue disease (MCTD) due to presence of swollen fingers, Raynaud's phenomenon, muscle weakness, positive anti-U1RNP antibody, pericarditis and interstitial pneumonia. Although the histology from a transbronchial lung biopsy (TBLB) indicated organizing pneumonia, corticosteroid therapy was postponed for two months at the patient's request. She died 8 weeks later from acute progressive interstitial pneumonia in spite of the administration of intravenous cyclophosphamide combined with prednisolone. The autopsy revealed exudative and organizing diffuse alveolar damage (DAD). Previous reports have shown that DAD is an extremely rare pulmonary complication in MCTD. This report presents a case of MCTD with acute respiratory failure. This case thus suggests that this therapy should be administered as soon as possible.
Background TIM-3 and CD39 are co-expressed in tumor-infiltrating T cells and antigen-presenting cells and considered to act as negative regulators of anti-tumor immunity. TIM-3 has multiple ligands including galectin-9, phosphatidylserine, CEA-CAM-1 and HMGB1. Although galectin-9 induces apoptosis in T cells via TIM-3, most of the TIM-3 antibodies under clinical development only partially block the galectin-9-binding to TIM-3. Adenosine is an immunosuppressive metabolite that suppresses T and NK cells. Inhibition of ATP-hydrolysis by purinergic ectoenzyme CD39 may recover anti-tumor immunity through reducing adenosine level in tumor microenvironment. We report herein BP1210, a novel TIM-3 biparatopic antibody (BpAb), that blocks the binding of multiple ligands including galectin-9 and BP1212, a bispecific antibody (BsAb) against TIM-3 and CD39, that blocks TIM-3-signaling and adenosine-mediated immune suppression. Methods The antibodies against TIM-3 and CD39 were cloned from mice immunized with recombinant proteins. Optimal combinations of clones were selected by functional assay for BpAb and BsAb, then the CDRs were grafted to human framework in effector null scFv-Fc format with knobs-intoholes mutations. Binding affinities and blocking/inhibiting activities were analyzed using recombinant proteins and cells endogenously expressing TIM-3 or CD39. The proliferation and cytokine production of T cells induced by antibodies were determined using human peripheral blood mononuclear cells (PBMCs). Anti-tumor efficacy of BP1210 was investigated in tumor models in huTIM-3 knock-in mice or in NOG mice transplanted with PBMCs. Results BP1210 BpAb that fully blocks the interaction of TIM-3 to both galectin-9 and phosphatidylserine, enhanced the activation of T cells stimulated by the antigen. i.e., BP1210 increased the population of IFNg + T cells, the production of cytokines, and suppressed the apoptosis of T cells, which are higher than other TIM-3 antibodies that fully blocks the binding to phosphatidylserine but not to galectin-9. in vivo studies showed that BP1210 retards the tumor growth and enhances the tumor-growth suppression by anti-PD-L1 antibody. BP1212 BsAb preferentially bound to the CD39 + TIM-3 + cells (exhausted T cells and APCs) and effectively blocked the enzymic activity of CD39 and binding to TIM-3 ligands in these cells. BP1212 augmented the proliferation and cytokine production of T cells, suggesting that BP1212 enhances the T cell immunity even in immunosuppressive tumor microenvironment. Conclusions BP1210 and BP1212 show the advantages over conventional TIM-3 and CD39 antibodies in T cell-mediated tumor immunity. Our engineered antibodies with novel combinations of antibody clones against immune checkpoints will provide new therapeutic options of tumor immunotherapy. Ethics Approval The present study was approved by the Institutional Ethics Committee of BrightPath Biotherapeutics Co., Ltd.(approved number: ERD-01). Animal studies were approved by the Institutional Animal Care and Use Committee (ap...
BackgroundT cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) is a part of modules expressed on dysfunctional or exhausted T cells as well as dendritic cells and has emerged as a target for several therapeutic antibodies that are under clinical development. Co-blockade of TIM-3 and PD-1 results in tumor regression in preclinical models and improves anticancer T cell responses in patients with advanced cancers. TIM-3 has been reported to have multiple ligands including galectin-9, phosphatidylserine, CEACAM-1 and HMGB1, which bind to different regions on the extracellular domain of TIM-3. Most of the TIM-3 antibodies developed to date are intended to inhibit phosphatidylserine that binds to the pocket in TIM-3 immunoglobulin V domain. Galectin-9 binds to carbohydrate motifs on the opposite side of phosphatidylserine-binding site in immunoglobulin V domain and thereby induces cell death in TIM-3+ T cells. We report herein novel antibodies that block TIM-3 binding to multiple ligands including these two important ligands simultaneously.MethodsAnti-TIM-3 antibodies were generated by immunizing mice with a purified recombinant TIM-3 protein and TIM-3-expressing mammalian cell line. Phage display libraries were constructed using cDNAs of splenocytes and lymph node cells of the immunized mice, then subjected to the biopanning using recombinant TIM-3 proteins. After analyzing specificities and affinities to the TIM-3 protein, scFvs obtained were classified by epitope bin and inhibitory effects on TIM-3 binding to the multiple ligands. The scFvs were converted to scFv-Fc to generate biparatopic (bispecific) antibodies.ResultsAt least five classes of TIM-3 antibodies were obtained, and each class was grouped into different epitope bins and has unique inhibitory profiles for multiple ligands of TIM-3. Their biparatopic (bispecific) forms were produced from the scFv clones and subjected to the analyses of TIM-3 binding, inhibition of ligand binding, and immune activation. As expected, the biparatopic antibodies that recognize two different epitopes showed higher affinity and specificity to TIM-3 than monospecific forms. A lead biparatopic antibody that block the binding of TIM-3 to galectin-9 and phosphatidylserine showed remarkable potency on T cell activation, protection from exhaustion and apoptotic cell death of T cells as well as more potent anti-tumor efficacy.ConclusionsThis study demonstrates the successful development of a novel biparatopic antibody that blocks the binding of TIM-3 to phosphatidylserine and galectin-9 simultaneously. The antibody shows the advantages over conventional TIM-3 antibodies in reducing T cell exhaustion and potentially manipulated for the development of human monoclonal antibodies for therapeutic treatment of cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.